Theriva Biologics files prospectus supplement for up to $4.02M ATM offering of common stock

Theriva Biologics, Inc.

Up to $4,019,597 of common stock may be sold through A.G.P./Alliance Global Partners as sales agent.
Sales will be at-the-market under Rule 415(a)(4); agent receives up to 3% commission.
Shares offered under existing S-3 shelf (File No. 333-279077) effective September 25, 2024.
No minimum sales obligation; company retains discretion over timing and amount.
Legal opinion on share validity from Parsons Behle & Latimer filed as Exhibit 5.1.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.